Best of the Week
Most Popular
1. Investing in a Bubble Mania Stock Market Trending Towards Financial Crisis 2.0 CRASH! - 9th Sep 21
2.Tech Stocks Bubble Valuations 2000 vs 2021 - 25th Sep 21
3.Stock Market FOMO Going into Crash Season - 8th Oct 21
4.Stock Market FOMO Hits September Brick Wall - Evergrande China's Lehman's Moment - 22nd Sep 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
7.AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
8.Why Silver Price Could Crash by 20%! - 5th Oct 21
9.Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
10.Global Stock Markets Topped 60 Days Before the US Stocks Peaked - 23rd Sep 21
Last 7 days
Inflation Consequences for the Stock Market, FED Balance Sheet - 24th Oct 21
To Be or Not to Be: How the Evergrande Crisis Can Affect Gold Price - 24th Oct 21
During a Market Mania, "no prudent professional is perceived to add value" - 24th Oct 21
Stock Market S&P500 Rallies Above $4400 – May Attempt To Advance To $4750~$4800 - 24th Oct 21
Inflation and the Crazy Crypto Markets - 23rd Oct 21
Easy PC Upgrades with Motherboard Combos - Overclockers UK Unboxing - MB, Memory and Ryzen 5600x CPU - 23rd Oct 21
Gold Mining Stocks Q3 2021 - 23rd Oct 21
Gold calmly continues cobbling its Handle, Miners lay in wait - 23rd Oct 21
US Economy Has Been in an Economic Depression Since 2008 - 22nd Oct 21
Extreme Ratios Point to Gold and Silver Price Readjustments - 22nd Oct 21
Bitcoin $100K or Ethereum $10K—which happens first? - 22nd Oct 21
This Isn’t Sci-Fi: How AI Is About To Disrupt This $11 Trillion Industry - 22nd Oct 21
Ravencoin RVN About to EXPLODE to NEW HIGHS! Last Chance to Buy Before it goes to the MOON! - 21st Oct 21
Stock Market Animal Spirits Returning - 21st Oct 21
Inflation Advances, and So Does Gold — Except That It Doesn’t - 21st Oct 21
Why A.I. Is About To Trigger The Next Great Medical Breakthrough - 21st Oct 21
Gold Price Slowly Going Nowhere - 20th Oct 21
Shocking Numbers Show Government Crowding Out Real Economy - 20th Oct 21
Crude Oil Is in the Fast Lane, But Where Is It Going? - 20th Oct 21
3 Tech Stocks That Could Change The World - 20th Oct 21
Best AI Tech Stocks ETF and Investment Trusts - 19th Oct 21
Gold Mining Stocks: Will Investors Dump the Laggards? - 19th Oct 21
The Most Exciting Medical Breakthrough Of The Decade? - 19th Oct 21
Prices Rising as New Dangers Point to Hard Assets - 19th Oct 21
It’s not just Copper; GYX indicated cyclical the whole time - 19th Oct 21
Chinese Tech Stocks CCP Paranoia, VIES - Variable Interest Entities - 19th Oct 21
Inflation Peaked Again, Right? - 19th Oct 21
Gold Stocks Bouncing Hard - 19th Oct 21
Stock Market New Intermediate Bottom Forming? - 19th Oct 21
Beware, Gold Bulls — That’s the Beginning of the End - 18th Oct 21
Gold Price Flag Suggests A Big Rally May Start Soon - 18th Oct 21
Inflation Or Deflation – End Result Is Still Depression - 18th Oct 21
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector - 18th Oct 21
US Economy and Stock Market Addicted to Deficit Spending - 17th Oct 21
The Gold Price And Inflation - 17th Oct 21
Went Long the Crude Oil? Beware of the Headwinds Ahead… - 17th Oct 21
Watch These Next-gen Cloud Computing Stocks - 17th Oct 21
Overclockers UK Custom Built PC 1 YEAR Use Review Verdict - Does it Still Work? - 16th Oct 21
Altonville Mine Tours Maze at Alton Towers Scarefest 2021 - 16th Oct 21
How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
The Only way to Crush Inflation (not stocks) - 14th Oct 21
Why "Losses Are the Norm" in the Stock Market - 14th Oct 21
Sub Species Castle Maze at Alton Towers Scarefest 2021 - 14th Oct 21
Which Wallet is Best for Storing NFTs? - 14th Oct 21
Ailing UK Pound Has Global Effects - 14th Oct 21
How to Get 6 Years Life Out of Your Overclocked PC System, Optimum GPU, CPU and MB Performance - 13th Oct 21
The Demand Shock of 2022 - 12th Oct 21
4 Reasons Why NFTs Could Be The Future - 12th Oct 21
Crimex Silver: Murder Most Foul - 12th Oct 21
Bitcoin Rockets In Preparation For Liftoff To $100,000 - 12th Oct 21
INTEL Tech Stock to the MOON! INTC 2000 vs 2021 Market Bubble WARNING - 11th Oct 21
AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
Stock Market Wall of Worry Meets NFPs - 11th Oct 21
Stock Market Intermediate Correction Continues - 11th Oct 21
China / US Stock Markets Divergence - 10th Oct 21
Can US Save Taiwan From China? Taiwan Strait Naval Battle - PLA vs 7th Fleet War Game Simulation - 10th Oct 21
Gold Price Outlook: The Inflation Chasm Between Europe and the US - 10th Oct 21
US Real Estate ETFs React To Rising Housing Market Mortgage Interest Rates - 10th Oct 21
US China War over Taiwan Simulation 2021, Invasion Forecast - Who Will Win? - 9th Oct 21
When Will the Fed Taper? - 9th Oct 21
Dancing with Ghouls and Ghosts at Alton Towers Scarefest 2021 - 9th Oct 21
Stock Market FOMO Going into Crash Season - 8th Oct 21
Scan Computers - Custom Build PC 6 Months Later, Reliability, Issues, Quality of Tech Support Review - 8th Oct 21
Gold and Silver: Your Financial Main Battle Tanks - 8th Oct 21
How to handle the “Twin Crises” Evergrande and Debt Ceiling Threatening Stocks - 8th Oct 21
Why a Peak in US Home Prices May Be Approaching - 8th Oct 21
Alton Towers Scarefest is BACK! Post Pandemic Frights Begin, What it's Like to Enter Scarefest 2021 - 8th Oct 21
AJ Bell vs II Interactive Investor - Which Platform is Best for Buying US FAANG Stocks UK Investing - 7th Oct 21
Gold: Evergrande Investors' Savior - 7th Oct 21
Here's What Really Sets Interest Rates (Not Central Banks) - 7th Oct 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Biotech Stocks With Near Term Catalysts

Companies / BioTech Jul 18, 2019 - 01:31 AM GMT

By: Joshua_Rodriguez

Companies Medical innovation is an incredible thing. In fact, as we continue to better understand the human body and cutting-edge biotechnology companies continue to produce innovative medicines, the average life expectancy in human beings is growing at a rate of about two months every year.

Not only is this innovation in medicine leading to a better quality of life and longer lifespan for countless patients, it is also leading strong investment opportunities. Driven by the fact that there are multiple catalysts along the process of drug development and incredible value once new drugs are approved, investor interest in the field of biotechnology is running high.

Many of these strong opportunities arise when biotechnology companies release news surrounding clinical progress, regulatory updates, and commercial success, some of the most common catalysts in the space. With that said, here’s a list of biotechnology companies with several catalysts ahead.

Amarin (AMRN): A Label Expansion Could Be Seriously Big News!

Amarin Corporation is best known for its flagship fish-oil drug, Vascepa. The treatment, approved for patients with high triglyceride levels, is already being met with strong uptake in the market. In fact, in a mid-year update published in early July, Amarin increased its revenue guidance from a midpoint of $350 million to a midpoint of $400 million, a move driven by expectations of strong Vascepa sales.

Nonetheless, the strong sales expectations may just be the tip of the iceberg should all go well with a coming catalyst. In September of last year, Amarin released the results of its Reduce-It cardiovascular outcomes study. The results proved to be impressive, suggesting decreased risk of cardiovascular complications among patients taking Vascepa.

Following these strong results, Amarin submitted a supplemental New Drug Application to the FDA looking to expand its label to include the reduction of cardiovascular risk in high risk patients as an indication. In late September, the FDA will be making its decision, and if positive, the stock could skyrocket. 

Previously, patients in the high cardiovascular risk category generally maintained heart health with once-daily baby aspirin. However, after the American Heart Association retracted this recommendation, there were no widely accepted options on the market, making the potential market opportunity massive.

Considering the strong sales growth that we’ve seen from Vascepa, any sales reports will likely prove to be catalystic events. Moreover, investors should watch closely as we near September, as the biggest catalyst of the company’s history may be hitting at the end of the month!

Hemispherx Biopharma (HEB): Multiple Data Readouts On The Horizons

Hemispherx biopharma is an immunopharma company. This means that the company is focused on innovative therapies that provide the body’s own immune system with the tools needed in order to fight some of the most devastating medical conditions.

Most notably is the company’s work in the field of immuno-oncology. This is an area where immunotherapies are used to enhance the body’s immune system, giving it the ability to fight against cancer.

In particular, Hemispherx Biopharma is working on a treatment option known as Ampligen. Approved in Argentina as an option for patients with myalgic encephalomyelitis/chronic fatigue syndrome, or ME/CFS, the treatment has already been approved for an indication not addressed by any other therapy on the market. While this is impressive in and of itself, I find the company’s work in the clinical setting to be far more meaningful.

Data from studies in both a wide variety of animal models of cancer, as well as in human subjects, suggests that Ampligen may modulate the tumor microenvironment. This microenvironment modulation has the potential to provide broad spectrum enhancement of the immune system to target and eliminate cancer cells.

Also, it seems as though Ampligen may be a double-edged sword in the fight against cancer. Data suggests efficacy as not only a mono-therapy, but potentially a combination therapy. In fact, data from various preclinical and clinical studies suggests synergies between Ampligen and immune-blockade inhibitor drugs. As such, it is believed that through the synergistic support provided by Ampligen to checkpoint inhibitors, these treatment options may see an increase in efficacy.

Due to the data suggesting potential efficacy in enhancing the treatment of a wide range of cancers, Ampligen is being studied across multiple programs in a robust series of clinical trials. With active clinical trials in ovarian, colorectal, and breast cancers, as well as plans for studies in renal cell carcinoma and melanoma, there are several catalysts to watch for ahead from Hemispherx.

BioMarin (BMRN): Multiple Catalysts And Political Safehaven

BioMarin is an interesting play. The biotechnology company is focused on the development of drugs for ultra-rare conditions. This strategy is smart for two reasons. First and foremost, treatments for ultra-rare diseases tend to move through the regulatory process faster and become instant market leaders when approved, as few to no options already exist.

Perhaps more importantly, given the political climate, treatments for rare conditions with limited population pools have a greenlight when it comes to commanding a high price tag. Election day is just over a year away, and early debates suggest that drug price reform will be a top priority on the checklist for Democrats.

However, due to the targeted rare indications, BioMarin is shielded from the risk associated with this reform. This ultimately separates the company from the majority of its biotechnology peers, giving it a strategic advantage.

At the moment, BioMarin has six revenue producers. The most recently launched option, Palynziq, is designed as a treatment for a rare condition known as phenylketonuria. In the first quarter, the drug generated $12.3 million in sales, and this figure is expected to climb to $100 million for the full 2019 year.

The company also has several established therapies on the market, including Vimizim, Kuvan, and Naglazyme, which are generating strong sales growth of their own.

Moving forward, the company’s treatment under development showing the most promise is a hemophilia A candidate known as valoctocogene roxaparvovec. Should this treatment be approved, it could push BioMarin to the next level, offering access to a market that is expected to grow to be worth nearly $17 billion in the years to come.

Considering the fact that BioMarin has multiple commercial-phase treatments, one of which is new to the market, sales reports ahead have the potential to turn into positive catalysts. Moreover, investors should watch valoctocgene roxaparvovec and the rest of the company’s robust pipeline for more opportunities ahead.

Horizon Therapeutics (HZNP): Strong Sales Growth With A Potential Blockbuster Approval Coming Down The Line

Horizon Therapeutics is best known for Krystexxa, a treatment that has been approved for patients with gout. Sales of the drug have been the cause of headlines, with 2018 sales growing 65% to $258.9 million.

The company intends to expand the label on the drug to include patients with uncontrolled gout who also suffer from chronic kidney disease. In fact, in June, the company announced that it began a study evaluating the combination of Krystexxa with methotrexate in patients with uncontrolled gout.

The company also has two rare disease drugs on the market that are seeing strong growth in sales. Ravicti, the company’s treatment for certain inborn urea cycle disorders, saw 2018 sales growth of 17%, generating sales of $226.6 million. Procysbi, a treatment indicated for the prevention of buildup of cystine crystals in the kidney, saw 2018 sales growth of 12%, climbing to $154.9 million.

Nonetheless, the company’s next drug may be its biggest yet. Horizon Therapeutics is working on teprotumumab as a potential treatment for protrusion of the eye as a result of inflammation behind the eye.

The company reduced data in April showing a dramatic reduction in eye bulging. In fact, 78% of patients responded to the treatment at week 24. Only 7.1% of patients in the placebo arm saw a response.

As a result of the strong data, it is expected that Horizon Therapeutics will be submitting a new drug application to the FDA any time now, with a potential approval in the coming months.

All in all, with multiple clinical studies underway, strong sales growth, and a potential approval from the FDA on the horizon, there are several catalysts to look forward to ahead.

Audentes Therapeutics (BOLD): Showing Strength In Rare Muscle Diseases

Finally, we have Audentes Therapeutics. The gene therapy technology company’s primary point of focus is on the development of treatments for patients with rare muscular diseases.

The company’s lead program is a gene therapy program assessing a candidate known as AT-132. AT-132 is being developed as a potential option for X-linked myotubular myopathy, an ultra-rare neuromuscular disorder.

The disorder is known to be caused by mutations to the myotubularin gene and usually results in muscle weakness. In severe cases, the condition can lead to respiratory failure.

Nonetheless, data from Audentes suggests that AT-132 could result in sustained improvement in neuromuscular and respiratory function. In fact, during the study, 3 patients that were dependent on ventilators achieved ventilator independence.

The company is also developing several other candidates as potential options in large neuromuscular indications, including Pompe disease, Crigler-Najjar and Deuchenne muscular dystrophy.

With a regulatory submission expected with regard to AT-132 relatively soon, as well as several ongoing clinical studies, Audentes Therapeutics will likely present several opportunities ahead.

Final Thoughts

Clinical, regulatory, and commercial catalysts drive some of the largest moves that we see in the biotechnology sector. The stocks mentioned above not only have several catalysts ahead, but previous data, including clinical results, sales reports, and regulatory feedback, suggest that these catalysts will be positive. So, keep your eyes peeled. 

This article is a paid advertisement. For full disclosures click here.

By Joshua Rodriguez

© 2019 Copyright Joshua Rodriguez - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in